Otonomy, Inc.
6275 Nancy Ridge Drive
Suite 100
San Diego
California
92121
United States
Tel: 858-242-5200
Fax: 858-200-0933
Website: http://www.otonomy.com/
Email: info@otonomy.com
About Otonomy, Inc.
Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to address diseases of the inner and middle ear. There are no drugs currently approved by the FDA for the lead indications we are currently pursuing for our product candidates. Our lead candidate AuriPro completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery, and we have submitted a request to the FDA for approval. If approved, we anticipate a commercial launch in early 2016 and are building our business and commercial team to meet the needs of this next stage of our growth.
182 articles with Otonomy, Inc.
-
Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
8/1/2022
Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the OTO-313 Phase 2 trial in tinnitus demonstrated no clinically meaningful benefit versus placebo for primary and secondary endpoints across all timepoints.
-
Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7/25/2022
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported financial results for the quarter ended June 30, 2022 and provided an update on its product pipeline and corporate activities.
-
Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update
7/18/2022
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the second quarter 2022 and provide a corporate update at 4:30 p.m. ET on July 25, 2022.
-
Otonomy to Participate in the H.C. Wainwright Global Investment Conference
5/18/2022
Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, announced its participation in the H.C. Wainwright Global Investment Conference.
-
Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
5/12/2022
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of preclinical data for OTO-825 at the upcoming American Society of Gene & Cell Therapy (ASGCT) Meeting being held May 16-19 in Washington, DC.
-
Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update
5/2/2022
Otonomy, Inc. today announced it will report financial results for the first quarter 2022 and provide a corporate update at 4:30 p.m. ET on May 9, 2022.
-
Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss
4/20/2022
Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 Results support clinical activity and tolerability findings from previous Phase 1/2 trial Enrollment in higher dose cohorts is ongoing with results expected in second half of 2022 Otonomy expects to initiate full dose-ranging Phase 2 efficacy trial by the end of 2022 Management will review results during a conference call today at 8:30 a.m. E
-
Otonomy to Participate in Two Upcoming Investor Conferences
2/28/2022
Otonomy, Inc. announced that management will participate in the following virtual investor conference events.
-
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
2/28/2022
Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, reported financial results for the quarter and year ended December 31, 2021 and provided an update on its product pipeline and corporate activities.
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
-
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
2/25/2022
Otonomy, Inc. announced that it will host a virtual Investor R&D Event from 10 a.m. - Noon ET on March 22, 2022.
-
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus
2/22/2022
Otonomy, Inc. today announced the completion of patient enrollment in the Phase 2 clinical trial of OTO-313 in tinnitus.
-
Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
2/17/2022
Otonomy, Inc. today announced it will report financial results for the fourth quarter and full year 2021 and provide a corporate update at 4:30 p.m. ET on February 28, 2022.
-
Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting
2/16/2022
Otonomy, Inc. today announced two upcoming presentations on the OTO-413 hearing loss program at the 49th Annual Scientific and Technology Meeting of the American Auditory Society (AAS) to be held February 24-26, 2022 in Scottsdale, Arizona.
-
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
1/25/2022
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 45th Annual MidWinter Meeting, to be held virtually during February.
-
Otonomy Reports Corporate and Product Pipeline Update
1/6/2022
Otonomy, Inc. today provided an update on its product pipeline and financial guidance.
-
Otonomy to Participate in the H.C. Wainwright BioConnect Conference
1/3/2022
Otonomy, Inc. today announced its participation in the H.C. Wainwright BioConnect Virtual Conference. A pre-recorded company presentation by the Otonomy management team will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on January 10, 2022.
-
Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
11/16/2021
Otonomy, Inc. today announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. Management will participate in a pre-recorded company fireside chat, which will be available on the conference website beginning at 10 a.m. ET / 7 a.m. PT on November 22, 2021.
-
Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/10/2021
Otonomy, Inc. The company will host a conference call and webcast today at 4:30 p.m. ET to discuss recent highlights and financial results.
-
Otonomy to Report Third Quarter 2021 Financial Results and Provide Corporate Update
11/3/2021
Otonomy, Inc. today announced it will report financial results for the third quarter 2021 and provide a corporate update at 4:30 p.m. ET (1:30 p.m. PT) on November 10, 2021.